Registration - In-house Corporation

AstraZeneca Canada Inc. / Gaby Bourbara, President

Registration Information

In-house Corporation name: AstraZeneca Canada Inc.
Responsible Officer Name: Gaby Bourbara, President
Responsible Officer Change History
Initial registration start date: 2007-03-08
Registration status: Active
Registration Number: 957438-15042

Associated Communications

Total Number of Communication Reports: 205

Monthly communication reports in the last 6 months: 21

Version 15 of 66 (2012-03-15 to 2013-02-28)

Registration versions:

Version 15 of 66 (2012-03-15 to 2013-02-28)

Lobbying Information

Subject Matters

Aboriginal Affairs
Constitutional Issues
Consumer Issues
Environment
Health
Industry
Intellectual Property
Internal Trade
International Development
International Relations
International Trade
Justice and Law Enforcement
Regional Development
Research and Development
Science and Technology
Taxation and Finance

Subject Matter Details

Policies or Program

Canada's Access to Medicines Regime (CAMR) with regard to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.
Canada's Food and Consumer Safety Action Plan with regard to ensuring that patient safety is a priority in a modern, efficient and internationally harmonized regulatory system that must be evidence-based, efficient and continuous while supporting timely access to innovative medicines and vaccines for Canadians, protecting intellectual property rights and preserving competitive research advantage.
Cost Recovery Initiative, ensuring a framework where user fees adequately fund a safe and efficient review process.
National Pharmaceutical Strategy (NPS) with regard to ensuring development or implementation of any policies or programs include consultations with all affected stakeholders and focus on bettering access to medicines for Canadians.
Patented Medicines Price Review Board (PMPRB) with regard to ensuring that PMPRB Guidelines, Policies and Procedures reflect PMPRB mandate to ensure that prices charged for patented medicines in Canada are not excessive and that potential changes consider impact to the pharmaceutical industry.
Science and Technology (S&T) Strategy with regard to ensuring that the implementation of that strategy encourages a public policy environment that attracts business investment in innovation and enhances the ability of Canadian industry to compete internationally.
Scientific Research and Experimental Development (SR&ED) Tax Incentive Program with regard to expansion of eligible expenditures to recognize the impact on innovation and the research and development (R&D) investment by the pharmaceutical industry in Canada.
The Canada-European Union Comprehensive Economic and Trade Agreement (CETA) negotiations with respect to biopharmaceuticals and intellectual property right protection.

Policies or Program, Regulation

Blueprint for Renewal with regard to ensuring a modern, efficient and internationally harmonized regulatory system that must be evidence-based, efficient and continuous while supporting timely access to innovative medicines and vaccines for Canadians, protecting intellectual property rights and preserving competitive research advantage.

Regulation

Patented Medicine Prices Review Board (PMPRB) with regard to ensuring guidelines also provide incentives for innovation through research and development in addition to PMPRB mandate of protection from excessive prices.
Patented Medicines (Notice Of Compliance) Regulations with regard to ensuring that Canada's intellectual property (IP) laws and regulations are internationally competitive and continue to provide a stable and predictable business environment to encourage continued pharmaceutical investment in Canada.

Communication Techniques

Written communication
Oral communication

Government Institutions

Aboriginal Affairs and Northern Development Canada
Agriculture and Agri-Food Canada (AAFC)
Atlantic Canada Opportunities Agency (ACOA)
Canada Revenue Agency (CRA)
Canadian Institutes of Health Research (CIHR)
Canadian International Development Agency (CIDA)
Canadian International Trade Tribunal (CITT)
Environment Canada
Federal Office of Regional Development – Quebec (FORD[Q])
Finance Canada (FIN)
Foreign Affairs and International Trade Canada (DFAITC)
Health Canada (HC)
House of Commons
Industry Canada
Members of the House of Commons
National Defence (DND)
National Research Council (NRC)
Natural Sciences and Engineering Research Council (NSERC)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Privy Council Office (PCO)
Public Health Agency of Canada (PHAC)
Revenue Canada (RC)
Royal Canadian Mounted Police (RCMP)
Senate of Canada
Treasury Board Of Canada Secretariat (TBS)
Veterans Affairs Canada (VAC)
Western Economic Diversification Canada (WD)

In-house Corporation Details

Description of activities

AstraZeneca is the largest research-based pharmaceutical company in Canada and one of the largest pharmaceutical companies in the world. Defined by the belief that "Health Connects Us All," AstraZeneca is a company that is focused on making a meaningful difference to patients' lives through collaborations. In Canada, we invest approximately $100 million annually in research and development and charitable donations. The company employs approximately 850 people across Canada who strive to make the most meaningful difference to patient health through the discovery, development and marketing of our great medicines. Most of our Canadian employees work at our high-tech headquarters in Mississauga, Ontario, while 125 highly-skilled scientists work at our world-class basic pain research centre in Montréal, Québec. AstraZeneca Research & Development Montréal (AZRDM) is a leader in pain control research, and scientists at the facility are focused on finding new and innovative therapeutic solutions to treat acute and chronic pain. Our innovative and extensive product portfolio focuses on six key areas of medicine: gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease.

Responsible officer name and position during the period of this registration

Elaine Campbell, President and Chief Executive Officer

Government funding

No government funding was received during the last completed financial year.

In-house Corporation Contact Information

Address:
1004 Middlegate Road
Mississauga, ON L4Y 1M4
Canada

Telephone number: 905-615-6883

Parent Company Information

AstraZeneca PLC
- 2 Kingdom Street
  London W26BD
  United Kingdom

Subsidiary Beneficiary Information

AstraZeneca Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

Lobbyists Details

Senior Officers whose lobbying activities represent less than 20% of their Duties

Elaine Campbell, President and Chief Executive Officer | No public offices held
Mark Findlay, Vice President, Access & External Affairs | No public offices held
Neil Maresky, Vice President, Scientific Affairs | No public offices held
Crawford Wright, Chief Compliance and Privacy Officer | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Tara Bingham, Federal Government Affairs | Public offices held
Claudia Neuber, Director, Pricing & Contracting | No public offices held

AstraZeneca Canada Inc.

The following names have been used on or after July 2, 2008

Name	From	To
AstraZeneca Canada Inc.	2008-07-31	current

The following names have been used before July 2, 2008

AstraZeneca Canada Inc.

AstraZeneca Canada Inc.

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
Gaby Bourbara	2024-03-01	Current
Kiersten Combs	2021-09-01	2024-03-01
Jane Chung	2019-11-01	2021-09-01
Daniel Smedley	2019-08-01	2019-11-01
Jamie Freedman	2017-11-28	2019-08-01
Ed Dybka	2015-01-02	2017-11-28
Elaine Campbell	2012-01-09	2015-01-02
Marion McCourt	2010-04-12	2012-01-09
Mark Jones	2007-03-08	2010-04-12

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Executive Assistant and Special Assistant for Parliamentary Affairs & Communications House of Commons, Belinda Stronach, M.P.	2004 to 2005	Not a designated office
Parliamentary Assistant House of Commons, Grant McNally, M.P.	1999 to 2004	Not a designated office
Researcher Office of the Leader of the Opposition, Preston Manning, M.P.	1997 to 1999	Not a designated office

Date Modified:: 2026-05-11

Search and menus

Language selection

Registration - In-house Corporation

AstraZeneca Canada Inc. / Gaby Bourbara, President

Registration Information

Associated Communications

Version 15 of 66 (2012-03-15 to 2013-02-28)

Version 15 of 66 (2012-03-15 to 2013-02-28)

Subject Matters

Subject Matter Details

Policies or Program

Policies or Program, Regulation

Regulation

Communication Techniques

Government Institutions

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties